Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs LY 3209590 (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Dec 2018 Status changed from active, no longer recruiting to completed.
- 20 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2018 Planned End Date changed from 1 Oct 2018 to 16 Oct 2018.